ARQULE - Read-Out Only in 2013
We remain positive on potential of Tivantinib (formerly ARQ-197, PhIII, c-MET inhibitor, 2nd/3rd-line NSCLC, partnered with Daiichi Sankyo, co-development, worldwide except Asia and Kyowa Hakko Kirin in Asia) but cautious on the B-RAF program, ARQ-736 (PhI, pan-Raf inhibitor, advanced solid tumors) based on our recent interaction with the management. It is an attractive acquisition target due to…. For more details, please read our report released on 13th September, 2011 on ARQL titled “Read-Out Only in 2013”.
COMPANIES MENTIONED
ARQULE
ARQULE
